High Court Urged To Weigh In On Drug 'Product-Hopping'
A drugmaker accused of "product hopping" consumers into buying a newer version of an Alzheimer's medication has urged the U.S. Supreme Court to determine whether patent owners violate federal antitrust laws...To view the full article, register now.
Already a subscriber? Click here to view full article